Compare Glenmark Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN GLENMARK PHARMA/
LUPIN
 
P/E (TTM) x 12.8 -64.0 - View Chart
P/BV x 1.9 3.0 64.2% View Chart
Dividend Yield % 0.5 0.7 71.9%  

Financials

 GLENMARK PHARMA   LUPIN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
LUPIN
Mar-21
GLENMARK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs5731,122 51.0%   
Low Rs195576 33.9%   
Sales per share (Unadj.) Rs387.8334.2 116.0%  
Earnings per share (Unadj.) Rs34.427.0 127.2%  
Cash flow per share (Unadj.) Rs50.146.6 107.5%  
Dividends per share (Unadj.) Rs2.506.50 38.5%  
Avg Dividend yield %0.70.8 85.0%  
Book value per share (Unadj.) Rs249.6300.1 83.2%  
Shares outstanding (eoy) m282.17453.68 62.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.02.5 39.0%   
Avg P/E ratio x11.231.4 35.6%  
P/CF ratio (eoy) x7.718.2 42.1%  
Price / Book Value ratio x1.52.8 54.4%  
Dividend payout %7.324.0 30.2%   
Avg Mkt Cap Rs m108,353385,072 28.1%   
No. of employees `000NANA-   
Total wages/salary Rs m23,43728,259 82.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m109,439151,630 72.2%  
Other income Rs m5021,363 36.8%   
Total revenues Rs m109,941152,993 71.9%   
Gross profit Rs m21,28925,669 82.9%  
Depreciation Rs m4,4368,874 50.0%   
Interest Rs m3,5311,406 251.1%   
Profit before tax Rs m13,82516,751 82.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,1244,485 91.9%   
Profit after tax Rs m9,70112,266 79.1%  
Gross profit margin %19.516.9 114.9%  
Effective tax rate %29.826.8 111.4%   
Net profit margin %8.98.1 109.6%  
BALANCE SHEET DATA
Current assets Rs m73,596139,864 52.6%   
Current liabilities Rs m42,01084,361 49.8%   
Net working cap to sales %28.936.6 78.8%  
Current ratio x1.81.7 105.7%  
Inventory Days Days769 9.6%  
Debtors Days Days86108 79.6%  
Net fixed assets Rs m67,09394,439 71.0%   
Share capital Rs m282907 31.1%   
"Free" reserves Rs m70,148135,229 51.9%   
Net worth Rs m70,430136,136 51.7%   
Long term debt Rs m38,888161 24,124.2%   
Total assets Rs m140,689234,302 60.0%  
Interest coverage x4.912.9 38.1%   
Debt to equity ratio x0.60 46,630.3%  
Sales to assets ratio x0.80.6 120.2%   
Return on assets %9.45.8 161.2%  
Return on equity %13.89.0 152.9%  
Return on capital %15.913.3 119.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m35,75351,027 70.1%   
Fx outflow Rs m12,02321,081 57.0%   
Net fx Rs m23,72929,946 79.2%   
CASH FLOW
From Operations Rs m11,31218,218 62.1%  
From Investments Rs m-6,752-12,396 54.5%  
From Financial Activity Rs m-4,418-18,853 23.4%  
Net Cashflow Rs m278-13,031 -2.1%  

Share Holding

Indian Promoters % 46.7 46.5 100.3%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 35.0 40.4 86.8%  
FIIs % 24.2 15.3 158.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 53.2 100.3%  
Shareholders   317,383 361,862 87.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUN PHARMA    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

LUPIN 2020-21 Annual Report Analysis (Annual Result Update)

Oct 19, 2021 | Updated on Oct 19, 2021

Here's an analysis of the annual report of LUPIN for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 21, 2022 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS